CareFusion to Distribute NeuroSENSE® Monitor in Scandinavia and Germany

SAN DIEGO, Dec. 15, 2010 -- CareFusion (NYSE: CFN), a leading, global medical technology company, announced today an agreement to distribute the NeuroWave Systems Inc. NeuroSENSE NS-701 Monitor in Scandinavia and Germany.

The NeuroSENSE Monitor is the latest generation, bilateral brain function monitor for assessing the adequacy of anesthesia and sedation in the operating room, intensive care unit, emergency room and other clinical settings. The system employs leading-edge technologies for signal acquisition and real-time processing of non-invasive electroencephalogram (EEG) signals on both sides of the patient's forehead and provides clinicians with the second-by-second brain status and trends for both brain hemispheres during anesthesia or sedation.

The NeuroSENSE is a unique brain function monitor for anesthesia and intensive care that provides simultaneously and without delay independent indices of brain activity for each brain hemisphere, which is important for detecting brain asymmetry due to, for example, unilateral pathology such as a stroke.

"The NeuroSENSE Monitor is a complementary addition to the CareFusion Nicolet portfolio of neurophysiologic and peri-operative product lines used today by clinicians in neurocritical care and operating room environments," said Mary de Sousa, vice president and general manager of the Nicolet product line at CareFusion. "The greater insight into the patient's brain function that the monitor provides can assist anesthesia providers in making decisions that may improve safety and patient care."

"We are committed to developing innovative brain monitoring technologies for improved cerebral protection and patient outcomes," said Tatjana Zikov, president of NeuroWave Systems, Inc. "We look forward to continuing our relationship with an innovative market and industry leader such as CareFusion."

About NeuroWave Systems Inc.
NeuroWave is a leading innovator in advanced brain monitoring for applications in anesthesia and neurology. Our technology is based on state-of-the-art signal processing of non-invasive brain waves. This growing company is an ISO 13485 manufacturer of the NeuroSENSE Monitor, now cleared for sales in Europe and other countries that recognize the CE mark. NeuroSENSE is the first brain monitor to provide real-time, independent feedback of the anesthetic effects on both cerebral hemispheres simultaneously. This greater and immediate insight into the patient's brain function assists anesthesia providers to make optimal decisions for improved and safer patient care. The company is headquartered and operates in Beachwood, Ohio, USA. For more information, visit www.neurowavesystems.com.

About CareFusion Corporation
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AirLife™, AVEA® and LTV® series of ventilators and respiratory products, ChloraPrep® skin prep products, MedMined™ services for infection surveillance, V. Mueller® and Snowden-Pencer® surgical instruments and Nicolet diagnostic and monitoring products. CareFusion employs more than 15,000 people across its global operations. More information may be found at www.carefusion.com.